These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 20093894

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The effect of omega-3 supplementation on pregnancy outcomes by smoking status.
    Kuper SG, Abramovici AR, Jauk VC, Harper LM, Biggio JR, Tita AT.
    Am J Obstet Gynecol; 2017 Oct; 217(4):476.e1-476.e6. PubMed ID: 28549983
    [Abstract] [Full Text] [Related]

  • 3. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJHM, van Eyck J, Groenwold RHH, Hasaart THM, Hummel P, Kars MM, Kwee A, van Oirschot CM, van Pampus MG, Papatsonis D, Porath MM, Spaanderman ME, Willekes C, Wilpshaar J, Mol BWJ, Bruinse HW.
    Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
    [Abstract] [Full Text] [Related]

  • 4. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA, Stoddard GJ, Fry RC, Esplin MS, Varner MW.
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
    Caritis SN, Venkataramanan R, Thom E, Harper M, Klebanoff MA, Sorokin Y, Thorp JM, Varner MW, Wapner RJ, Iams JD, Carpenter MW, Grobman WA, Mercer BM, Sciscione A, Rouse DJ, Ramin S, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network and Obstetric-Fetal Pharmacology Research Units Network.
    Am J Obstet Gynecol; 2014 Feb; 210(2):128.e1-6. PubMed ID: 24113254
    [Abstract] [Full Text] [Related]

  • 7. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC, Schoen CN, Frey H, Gimovsky AC, Springel E, Backley S, Berghella V.
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [Abstract] [Full Text] [Related]

  • 8. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
    Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY, Iams JD, Wapner RJ, Varner M, Carpenter M, Lo J, Thorp J, Mercer BM, Sorokin Y, Harper M, Ramin S, Anderson G, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Maternal-Fetal Medicine Units Network (MFMU).
    Obstet Gynecol; 2009 Feb; 113(2 Pt 1):285-92. PubMed ID: 19155896
    [Abstract] [Full Text] [Related]

  • 9. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
    Boelig RC, Locci M, Saccone G, Gragnano E, Berghella V.
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
    [Abstract] [Full Text] [Related]

  • 10. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
    Blackwell SC, Gyamfi-Bannerman C, Biggio JR, Chauhan SP, Hughes BL, Louis JM, Manuck TA, Miller HS, Das AF, Saade GR, Nielsen P, Baker J, Yuzko OM, Reznichenko GI, Reznichenko NY, Pekarev O, Tatarova N, Gudeman J, Birch R, Jozwiakowski MJ, Duncan M, Williams L, Krop J.
    Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
    [Abstract] [Full Text] [Related]

  • 11. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A, Vladutiu CJ, Dotters-Katz SK, Goodnight WH, Manuck TA.
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [Abstract] [Full Text] [Related]

  • 12. Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
    Price JT, Vwalika B, Freeman BL, Cole SR, Saha PT, Mbewe FM, Phiri WM, Peterson M, Muyangwa D, Sindano N, Mwape H, Smithmyer ME, Kasaro MP, Rouse DJ, Goldenberg RL, Chomba E, Stringer JSA.
    Lancet HIV; 2021 Oct; 8(10):e605-e613. PubMed ID: 34509197
    [Abstract] [Full Text] [Related]

  • 13. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
    Suresh S, Freedman A, Adams M, Hirsch E, Ernst LM.
    Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
    [Abstract] [Full Text] [Related]

  • 14. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial.
    Facchinetti F, Vergani P, Di Tommaso M, Marozio L, Acaia B, Vicini R, Pignatti L, Locatelli A, Spitaleri M, Benedetto C, Zaina B, DʼAmico R.
    Obstet Gynecol; 2017 Jul; 130(1):64-70. PubMed ID: 28594783
    [Abstract] [Full Text] [Related]

  • 15. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB, McIntire DD, McDonald J, Gard J, Turrichi P, Leveno KJ.
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [Abstract] [Full Text] [Related]

  • 16. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
    Nelson DB, McIntire DD, Leveno KJ.
    Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
    [Abstract] [Full Text] [Related]

  • 17. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [Abstract] [Full Text] [Related]

  • 18. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.
    Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, Varner M, Malone F, Iams JD, Mercer BM, Thorp J, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M, Anderson G, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
    N Engl J Med; 2007 Aug 02; 357(5):454-61. PubMed ID: 17671253
    [Abstract] [Full Text] [Related]

  • 19. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
    Bustos ML, Caritis SN, Jablonski KA, Reddy UM, Sorokin Y, Manuck T, Varner MW, Wapner RJ, Iams JD, Carpenter MW, Peaceman AM, Mercer BM, Sciscione A, Rouse DJ, Ramin SM, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
    Am J Obstet Gynecol; 2017 Sep 02; 217(3):369.e1-369.e9. PubMed ID: 28522317
    [Abstract] [Full Text] [Related]

  • 20. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth.
    Elimian A, Smith K, Williams M, Knudtson E, Goodman JR, Escobedo MB.
    Int J Gynaecol Obstet; 2016 Aug 02; 134(2):169-72. PubMed ID: 27168167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.